Data from this study have been previously published as abstract or proceedings of the ESVD/ECVD Annual Congress: Veterinary Dermatology 2010; 21: 531; and in New Trends in Allergy VII Congress; July, 2010 – Special Workshop CAD.
Masitinib decreases signs of canine atopic dermatitis: a multicentre, randomized, double-blind, placebo-controlled phase 3 trial
Version of Record online: 13 JUN 2011
© 2011 The Authors. Veterinary Dermatology. © 2011 ESVD and ACVD
Volume 22, Issue 6, pages 554–564, December 2011
How to Cite
Cadot, P., Hensel, P., Bensignor, E., Hadjaje, C., Marignac, G., Beco, L., Fontaine, J., Jamet, J.-F., Georgescu, G., Campbell, K., Cannon, A., Osborn, S. C., Messinger, L., Gogny-Goubert, M., Dubreuil, P., Moussy, A. and Hermine, O. (2011), Masitinib decreases signs of canine atopic dermatitis: a multicentre, randomized, double-blind, placebo-controlled phase 3 trial. Veterinary Dermatology, 22: 554–564. doi: 10.1111/j.1365-3164.2011.00990.x
Sources of Funding This study was financially supported by AB Science, SA, Paris, France, including a free supply of the drug. This work was partially financed by INSERM (Institut National de la Santé et de la Recherche Médicale), la Ligue Nationale Contre le Cancer (équipe labellisée PD) and ANR-MRAR (Agence Nationale pour la Recherche, grant Maladies Rares; P.D. and O.H.) and INCA (Institut National du Cancer, grant Translationnel; P.D. and O.H.).
Conflict of Interest Masitinib is under clinical development by the study sponsor, AB Science, SA, Paris, France. The sponsor was involved in the study design, data interpretation, manuscript preparation and submission. A.M. is an employee and shareholder of the study sponsor. O.H. and P.D. are consultants and shareholders of the study sponsor. E.B. is the recipient of a research grant from AB Science. No other conflicts of interest have been declared.
- Issue online: 25 OCT 2011
- Version of Record online: 13 JUN 2011
- Accepted 8 April 2011
Document S1. Masitinib in canine atopic dermatitis.
Table S1. Study flow chart.
Table S2. Evolution of CADESI-02 response in the mITT population over a 12-week treatment period, according to data sets of observed cases and missing data as failure.
Table S3. Distribution of dogs according to their pruritus score at baseline.
Table S4. Pruritus response rate in the control group at week 12 according to concomitant use of antibiotic, antifungal or antiseptic treatments and baseline pruritus – mITT population.
Figure S1. Representation of the variability of severity perception among pet owners (Bland and Altman method).
Figure S2. Representation of the variability of perception of changes among pet owners (Bland and Altman method).
Discussion on the bias in pruritus scoring.
|VDE_990_sm_DocumentS1.pdf||137K||Supporting info item|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.